NOVA-3 is not training a new structure-prediction model — we wrap best-of-breed open foundations and add the workflow, library, validation, and quantum layers on top. Hard numbers benchmarking NOVA-3 vs each model below publish Q3 '26.
What's being measured · Q3 '26
Single-chain folding accuracy: RMSD on a held-out antibody structure set vs. PDB ground truth
Multi-specific complex prediction: interface RMSD and DockQ on known bispecific co-crystal structures
Ranking consistency check: rank-order (Spearman) agreement between the module-anchored affinity estimate and SPR-measured affinity on a held-out set, reported with n. Engineered-window arms (attenuated CD3 / conditional 4-1BB, where the design target is a range, not "tighter is better") are assessed against their target window, not monotonic correlation. This is a retrospective consistency check, not a claim of de-novo predictive calibration.
Q3 '26 is a target, not a committed date. Results publish when ready, not when the calendar says.
Figure — Where NOVA-3 differs. On raw single-chain fold accuracy, NOVA-3 does not out-fold AF3, Chai, or ESMFold — it wraps those best-of-breed predictors rather than beating them. Its differentiation sits elsewhere: multi-specific composition from a curated module library upstream, and cryptographic provenance, quantum active-space corrections, and a wet-lab DBTL data flywheel downstream. Strictly qualitative — no benchmark numbers are claimed.
Honest framing: on raw folding accuracy, AlphaFold 3 and Chai-1 set the bar. NOVA-3 is not trying to beat them — we use them as building blocks. Our differentiation is upstream (multi-specific composability via the Module Library) and downstream (quantum-corrected refinement + cryptographic provenance + wet-lab flywheel). A pharma team using NOVA-3 gets AF3-grade folding plus the workflow that closes the loop to in-vitro PoC.